Inhibitors of the FASII Metabolic Pathway in Toxoplasma gondii: Advances and Therapeutic Perspectives
Authors:
- Claudia Jessica Castillo-VillanuevaCCClaudia Jessica Castillo-Villanueva
- Jhony Anacleto-SantosJAJhony Anacleto-Santos
- Teresa de Jesús López-PérezTLTeresa de Jesús López-Pérez
- Brenda Casarrubias-TabarezBCBrenda Casarrubias-Tabarez
- Teresa I. FortoulTFTeresa I. Fortoul
- Marcela Rojas-LemusMRMarcela Rojas-Lemus
- Nelly López-ValdezNLNelly López-Valdez
- Elisa Vega-ÁvilaEVElisa Vega-Ávila
- Fernando CalzadaFernando Calzada
- Perla Yolanda López-CamachoPLPerla Yolanda López-Camacho
- Norma Rivera-FernándezNRNorma Rivera-Fernández
Open Access
- 9 May 2026
- journal article
- review article
- Published by MDPI AG in Microorganisms
- Vol. 14 (5) , 1072
Abstract
Toxoplasma gondii is an obligate intracellular parasite of the phylum Apicomplexa and the causative agent of toxoplasmosis, a disease with a worldwide distribution that causes serious consequences in immunocompromised patients and during pregnancy. Current pharmacological treatments have significant limitations, including their toxicity, lack of efficacy against the chronic phase of the parasite, and low selectivity, highlighting the need to develop new therapeutic targets. One of the most promising targets is the fatty acid synthesis pathway II (FASII), a metabolic pathway located in the parasite’s apicoplast and absent in mammalian hosts. This review synthesizes the available evidence on FASII pathway inhibitors described to date, as well as their potential impact on the viability and development of T. gondii. Overall, the reviewed studies support the FASII pathway as an attractive therapeutic target for the development of more selective and effective treatments against toxoplasmosis.Keywords
Funding Information
- DGAPA-PAPIIT UNAM project (IN200524)
- SECIHTI (Formerly CONAHCYT) project (CF-2023-G370)
This publication has 79 references indexed in Scilit:
- 3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinumEuropean Journal of Medicinal Chemistry, 2023
- Characterization of functions in parasite growth and virulence of four Toxoplasma gondii genes involved in lipid synthesis by CRISPR-Cas9 systemParasitology Research, 2021
- Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screeningEuropean Journal of Medicinal Chemistry, 2019
- Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic ReviewDrugs in R&D, 2017
- Effect of Triclosan on Self-Assembly of Alkyl Ammonium Surfactants Adsorbed within Montmorillonite Galleries in Silicone Elastomer CompositesMacromolecular Symposia, 2014
- Modification of Triclosan Scaffold in Search of Improved Inhibitors for Enoyl‐Acyl Carrier Protein (ACP) Reductase in Toxoplasma gondiiChemMedChem, 2013
- Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductaseBioorganic & Medicinal Chemistry Letters, 2013
- Synthesis and evaluation of oryzalin analogs against Toxoplasma gondiiBioorganic & Medicinal Chemistry Letters, 2010
- Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4′-Substituted triclosan derivativesBioorganic & Medicinal Chemistry Letters, 2005
- Evaluation of fluorescence-based thermal shift assays for hit identification in drug discoveryAnalytical Biochemistry, 2004